In a bid to build its cardiovascular pipeline, Amgen has entered into two agreements with Arrowhead Pharmaceuticals to develop and commercialise RNA interference (RNAi) therapies for cardiovascular disease. The first was an exclusive license to Arrowhead's RNAi ARC-LPA programme targeting lipoprotein(a) and the second was an option to a worldwide, exclusive license for an RNAi therapy for an undisclosed genetically-validated cardiovascular target. The overall agreement included an upfront cash payment of US$35 M, US$21.5 M equity investment by Amgen in Arrowhead stock and US$617 M in milestones and royalties.